SARS-CoV-2 infects human cardiomyocytes promoted by inflammation and oxidative stress

  • Melina Tangos (Shared first author)
  • Heidi Budde (Shared first author)
  • Detmar Kolijn (Shared first author)
  • Marcel Sieme (Shared first author)
  • Saltanat Zhazykbayeva
  • Mária Lódi
  • Melissa Herwig
  • Kamilla Gömöri
  • Roua Hassoun
  • Emma Louise Robinson
  • Toni Luise Meister
  • Kornelia Jaquet
  • Árpád Kovács
  • Julian Mustroph
  • Katja Evert
  • Nina Babel
  • Miklós Fagyas
  • Diana Lindner
  • Klaus Püschel
  • Dirk Westermann
  • Hans Georg Mannherz
  • Francesco Paneni
  • Stephanie Pfaender
  • Attila Tóth
  • Andreas Mügge
  • Samuel Sossalla
  • Nazha Hamdani

Related Research units

Abstract

INTRODUCTION: The respiratory illness triggered by severe acute respiratory syndrome virus-2 (SARS-CoV-2) is often particularly serious or fatal amongst patients with pre-existing heart conditions. Although the mechanisms underlying SARS-CoV-2-related cardiac damage remain elusive, inflammation (i.e. 'cytokine storm') and oxidative stress are likely involved.

METHODS AND RESULTS: Here we sought to determine: 1) if cardiomyocytes are targeted by SARS-CoV-2 and 2) how inflammation and oxidative stress promote the viral entry into cardiac cells. We analysed pro-inflammatory and oxidative stress and its impact on virus entry and virus-associated cardiac damage from SARS-CoV-2 infected patients and compared it to left ventricular myocardial tissues obtained from non-infected transplanted hearts either from end stage heart failure or non-failing hearts (donor group). We found that neuropilin-1 potentiates SARS-CoV-2 entry into human cardiomyocytes, a phenomenon driven by inflammatory and oxidant signals. These changes accounted for increased proteases activity and apoptotic markers thus leading to cell damage and apoptosis.

CONCLUSION: This study provides new insights into the mechanisms of SARS-CoV-2 entry into the heart and defines promising targets for antiviral interventions for COVID-19 patients with pre-existing heart conditions or patients with co-morbidities.

Bibliographical data

Original languageEnglish
ISSN0167-5273
DOIs
Publication statusPublished - 01.09.2022

Comment Deanary

Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

PubMed 35643215